Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/88346
DC Field | Value | Language |
---|---|---|
dc.contributor | Chinese Mainland Affairs Office | - |
dc.contributor | Department of Applied Biology and Chemical Technology | - |
dc.creator | Qu, Z | - |
dc.creator | Lin, Y | - |
dc.creator | Mok, DKW | - |
dc.creator | Bian, Q | - |
dc.creator | Tai, WCS | - |
dc.creator | Chen, S | - |
dc.date.accessioned | 2020-10-29T01:02:36Z | - |
dc.date.available | 2020-10-29T01:02:36Z | - |
dc.identifier.uri | http://hdl.handle.net/10397/88346 | - |
dc.language.iso | en | en_US |
dc.publisher | Ivyspring International | en_US |
dc.rights | © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. | en_US |
dc.rights | The following publication Qu Z, Lin Y, Mok DKW, Bian Q, Tai WCS, Chen S. Arnicolide D Inhibits Triple Negative Breast Cancer Cell Proliferation by Suppression of Akt/mTOR and STAT3 Signaling Pathways. Int J Med Sci 2020; 17(11):1482-1490, is available at https://doi.org/10.7150/ijms.46925 | en_US |
dc.subject | Akt/mTOR | en_US |
dc.subject | Arnicolide D | en_US |
dc.subject | STAT3 | en_US |
dc.subject | Triple negative breast cancer | en_US |
dc.title | Arnicolide D inhibits triple negative breast cancer cell proliferation by suppression of akt/mTOR and STAT3 signaling pathways | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.spage | 1482 | - |
dc.identifier.epage | 1490 | - |
dc.identifier.volume | 17 | - |
dc.identifier.issue | 11 | - |
dc.identifier.doi | 10.7150/ijms.46925 | - |
dcterms.abstract | Triple-Negative Breast Cancer (TNBC) is a most dangerous breast cancer subtype. The naturally occurring sesquiterpene lactone, arnicolide D (AD), has proven effective against a variety of tumors, however, the inhibitory effects of AD against TNBC and the underlying mechanisms remain unclear. In the present study, two TNBC cell lines (MDA-MB-231 and MDA-MB-468) and an MDA-MB-231 xenograft mouse model were employed to investigate the anti-TNBC effects of AD in vitro and in vivo. Cell viability was assessed by MTT assay. Cell cycle arrest and apoptosis were analyzed by flow cytometry. Protein levels were determined by immunoblotting. In vitro studies demonstrated that AD significantly decreased cell viability, and induced G2/M cell cycle arrest and apoptosis. In vivo assays showed that oral administration of 25 or 50 mg/kg AD for 22 days led to a reduction of tumor weights by 24.7% or 41.0%, without appreciable side effects. Mechanistically, AD inhibited the activation of Akt/mTOR and STAT3 signaling pathways. Based on our findings, AD is a promising candidate for development as an adjunctive therapeutic drug for TNBC. | - |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | International Journal of medical sciences, 2020, v. 17, no. 11, p. 1482-1490 | - |
dcterms.isPartOf | International Journal of medical sciences | - |
dcterms.issued | 2020 | - |
dc.identifier.scopus | 2-s2.0-85087922549 | - |
dc.identifier.pmid | 32669950 | - |
dc.identifier.eissn | 1449-1907 | - |
dc.description.validate | 202010 bcma | - |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | OA_Scopus/WOS | en_US |
dc.description.pubStatus | Published | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Qu_Arnicolide-D_inhibits_triple.pdf | 2.74 MB | Adobe PDF | View/Open |
Page views
30
Last Week
0
0
Last month
Citations as of Sep 24, 2023
Downloads
1
Citations as of Sep 24, 2023
SCOPUSTM
Citations
6
Citations as of Sep 28, 2023
WEB OF SCIENCETM
Citations
5
Citations as of Sep 28, 2023

Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.